Lege Artis Medicinae

[Rapid-acting human insulin analogues: new possibilities in the therapy of diabetes mellitus]


APRIL 20, 2002

Lege Artis Medicinae - 2002;12(04)

[Modifications of the insulin molecule at the end of the B chain resulted in the development of some new, more physiological meal-related insulins, the rapid acting human insulin analogues. This survey summarises the characteristics (structure, absorption, immunogenicity, efficacy and safety) and the conditions of clinical application of the rapid-acting insulin analogues available at the moment in Hungary. Furthermore, authors evaluate the effect of application of rapid-acting insulin analogues on the quality of life and glycaemic control of the patients. The collaboration between the well-prepared health-care team and the well-educated and cooperative diabetic patient using rapid-acting insulin analogue could lead to a level of freedom of lifestyle that approximates that of healthy people.]


  1. Diabétesz Gondozási Nemzeti Központ, Szent Imre Kórház, IV. Belgyógyászati Osztály, Budapest
  2. Diabétesz Gondozási Nemzeti Központ, Semmelweis Egyetem, ÁOK, I. Sz. Belgyógyászati Klinika, Diabétesz Részleg, Budapest



Further articles in this publication

Lege Artis Medicinae

[Statin for everyone? - Aspects of treatment]


Lege Artis Medicinae

[Recognition of mental disorders in primary care]


[BACKGROUND - Several studies have shown that a substantial part of patients with mood and anxiety disorders seeks help at their primary care physician. It is well known that recognition of these disorders cause difficulties for general practitioners. In our study starting in 1998, we attempted to map the psychiatric disorders present in primary care patients. This paper investigates the factors that may contribute to the difficulties in recognition and diagnosis of mental disorders. METHOD - 1815 primary care patients in 12 general practice offices has been evaluated for mood and/or anxiety disorders with DIS interview. The DIS diagnosis was compared with complaints and symptoms of patients and diagnosis given by their GPs. RESULTS - Diagnosis given by GPs and DIS evaluation showed low concordance. The main factor in this proved to be the presence of somatic disorders, whereas socio-demographic factors played little role. The highest concordance of diagnosis was found when acute or chronic somatic disorders were not present.]

Lege Artis Medicinae



Lege Artis Medicinae



Lege Artis Medicinae

[Cochlear implantation: results and perspectives in the therapy of profound deafness in Hungary]


[Cochlear implantation is a relatively new method that revolutionised the therapy of bilateral deafness and profound hearing loss of inner ear origin which could not be treated with surgery before. The function of the inner ear that is irreversibly damaged either because of congenital causes, trauma, infection or unknown origin is substituted by cochlear implant. In implanted patients the device fixed in the middle ear transmits the previously transformed electrical stimuli directly to the cochlear nerve via the electrodes inserted in the inner ear. Prior to implantation there is a detailed selection process and also a lengthy, followed by a several-year-long rehabilitation period, resulting in nearly perfect speech discrimination without lipreading in most cases. Cochlear implantation is indicated in the first place in case of prelingual deafs under 5 and postlingual deaf patients of any age. In the article authors discuss the theoretical basis, technical background and indications of cochlear implantation, while also providing an overview of the whole procedure from the preoperative examinations to postoperative rehabilitation.]

All articles in the issue

Related contents

Lege Artis Medicinae



[Insulin aspart (B28 Asp-insulin), which is produced by recombinant DNA technology, is a fast-acting insulin analogue. Due to the aspartate for proline substitution at position 28 of the Bchain, the insulin molecule's tendency for selfassociation is diminished, therefore, insulin aspart rapidly dissociates into dimeric and monomeric forms and absorbs quickly and easily after subcutaneous administration. Compared to human regular insulin, insulin aspart has a faster onset of activity, a higher plasma peak and a shorter duration of action. Overall, the pharmacokinetic profile of insulin aspart better mimics the physiological postprandial insulin secretion. Therefore, insulin aspart can be used for prandial insulin substitution in order to decrease postprandial blood glucose excursion. It should be administered immediately before meals, but some observations suggest that it can also be used after finishing meal. This allows a more flexible lifestyle for patients. Insulin aspart can be used in both type 1 and type 2 diabetes. Compared to regular human insulin, a moderate decrease in the HbA1c values and fewer nocturnal hypoglycaemic events are expected from insulin aspart use. Insulin aspart is appropriate for pump treatment as well. It has recently been approved for use in pregnancy, whereas for children and adolescents the expected benefits should be weighed against the more modest clinical experience available. Similarly to other insulin analogues, results of long-term clinical investigations with insulin aspart with regard to the development of complications are not yet available.]

Lege Artis Medicinae

[Insulin pump therapy in type 1 diabetes in the light of efficacy, safety, and quality of life]


[The level of glycaemic control necessary to achieve optimal outcomes in subjects with type 1 diabetes mellitus typically requires intensified insulin therapy using multiple daily injections or continuous subcutaneous insulin infusion (CSII). For CSII, the insulins of choice are the rapid-acting insulin analogues: insulin aspart, insulin lispro and insulin glulisine. The advantages of CSII over multiple daily injections in adult and paediatric populations with type 1 diabetes include superior glycaemic control, lower insulin requirements and better health-related quality of life/patient satisfaction. An association between CSII and reduced hypoglycaemic risk is more consistent in children/adolescents than in adults. The use of CSII is widely recommended in both adult and pediatric type 1 diabetes mellitus populations, but is limited in pregnant patients. The review also discusses the result of the “A non-interventional trial to observe the effect of the use of Accu Chek Combo device on quality of life and metabolic control“(COM-1101-HU 1.3).]

Lege Artis Medicinae

[Switching from human basal insulin to once daily insulin detemir in type 2 diabetic patients treated by basal-bolus regimen - Results from the LEONCET2, an observational, prospective, multicenter study]


[Insulin analogues have been developed in order to overcome some drawbacks of human insulins. Switching from a human insulin-based basal- bolus regimen to once daily detemir could result in improved metabolism and increased safety of the therapy. We assessed the effects of switching from human NPH-insulin to once daily detemir insulin in patients with type 2 diabetes mellitus treated with a basal-bolus insulin regimen. We evaluated the data of 1,474 patients with diabetes (age: 59.1±9.8 years, body weight 89.6±8.6 kg, BMI 31.6±5.4 kg/m2) in an observational, prospective, 24-week, multicenter study. All patients were treated with a basal-bolus regimen consisting of human NPH as basal insulin and a human or analogue insulin as bolus insulin. After enrollment, patients received once daily detemir insulin instead of NPH-insulin, while treatment with bolus insulin was continued. Patients were examined at weeks 12 and 24. By week 24, the mean HbA1c value, irrespective of BMI-categories, decreased significantly (p<0.0001) from 8.63±1.01% by 0.79±0.63%. Fasting blood glucose level decreased from 8.86±1.78 mmol/l to 7.09±1.31 mmol/l; p<0.0001). The target level of HbA1c (<7.0%) was reached by 194 patients (13.1%). The patients’ body weight decreased significantly by week 12 (-0.69±2.00 kg; p<0.0001) and by week 24 (-1.28±2.80 kg; p<0.0001). The changes were more pronounced in higher than in lower BMI-categories (p for trend <0.0001). The mean daily doses of basal insulin were increased from 0.28 IU/kg to 0.33 IU/kg while those of bolus insulins were not changed. The rate of severe hypoglycaemic events decreased significantly (p=0.048) from 2.95 [daytime 1.02, nocturnal 1.93] to 0.06 [daytime 0.04, nocturnal 0.02] episodes/patient-year. In patients with type 2 diabetes mellitus treated with basal-bolus regimen, switching from human basal insulin to once daily insulin detemir results in a significantly improved metabolism, as well as fewer hypoglycaemic events and decreased body weight. Nevertheless, the low rate of patients reaching the glycaemic target implicates that some factors other than an appropriate basal insulin substitution have a role in achieving an optimal metabolic control.]

Clinical Neuroscience



[This review article is concerned with the role of electromyography (EMG) in the clinical diagnostic work. After a summary on the developmental history of electromyography, the most important EMG methods are presented. The modern quantitative EMG methods are sensitive and accurate thus providing important information in the evaluation of various neurological diseases, particularly in the diagnosis of neuromuscular disorders. The EMG examinations are useful tool for the clinician only if the applied methods are carefully chosen and properly performed and the rules of interpretation are strictly followed.]

Lege Artis Medicinae



[Insulin detemir is a neutral, soluble, long-acting insulin analogue in which the amino acid threonineB30 has been removed and the LysB29 acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to dihexamerisate and reversibly bind to human albumin upon administration. This brand new principle (self association and albumin binding) ensures slow absorption and a prolonged and consistent metabolic effect without a marked peak for up to 24 hours in patients both with type 1 and type 2 diabetes mellitus. Results of large clinical trials have shown that detemir can be efficiently used as basal insulin, supplemented with human regular insulin or aspart insulin taken before the main meals, in both type 1 and type 2 diabetes. Available data clearly demonstrate that the use of this insulin is associated with decreased variability of the fasting blood glucose values. In some of the studies the risk of (mostly nocturnal) hypoglycaemic episodes also dropped. It is important to note that patients using insulin detemir gained less or no weight compared to the group of patients treated with neutral protamine Hagedorn (NPH) insulin. Evaluation of long-term and wide-spread application of detemir needs further observations. Such trials are being conducted worldwide.]